Antonino C. Musolino

Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer.

Journal: JAMA network open

Published: July 14, 2026

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 06, 2026

Multiparametric whole-body magnetic resonance imaging in breast cancer management: A prospective study.

Journal: Tumori

Published: June 04, 2026

Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients.

Journal: Frontiers in oncology

Published: May 08, 2026

Artificial intelligence for predicting pathological complete response to neoadjuvant therapy in triple-negative breast cancer: A systematic review and meta-analysis.

Journal: Breast (Edinburgh, Scotland)

Published: April 24, 2026

Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 11, 2026

Elucidating PI3K/AKT/PTEN Pathway Alterations at Single-Cell Level in CTCs From HR+/HER2- Metastatic Breast Cancer.

Journal: Cancer science

Published: February 19, 2026

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 18, 2025

Screening children and adolescents for cutaneous malignant melanoma: the impossible trade-off between life-years saved and unnecessary biopsies.

Journal: Frontiers in oncology

Published: October 16, 2025

The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives.

Journal: Tumori

Published: September 15, 2025

Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions.

Journal: Cancers

Published: September 01, 2025

Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer.

Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer.

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

Multiparametric whole-body magnetic resonance imaging in breast cancer management: A prospective study.

Multiparametric whole-body magnetic resonance imaging in breast cancer management: A prospective study.

Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients.

Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients.

Artificial intelligence for predicting pathological complete response to neoadjuvant therapy in triple-negative breast cancer: A systematic review and meta-analysis.

Artificial intelligence for predicting pathological complete response to neoadjuvant therapy in triple-negative breast cancer: A systematic review and meta-analysis.

Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer.

Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer.

Elucidating PI3K/AKT/PTEN Pathway Alterations at Single-Cell Level in CTCs From HR+/HER2- Metastatic Breast Cancer.

Elucidating PI3K/AKT/PTEN Pathway Alterations at Single-Cell Level in CTCs From HR+/HER2- Metastatic Breast Cancer.

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Screening children and adolescents for cutaneous malignant melanoma: the impossible trade-off between life-years saved and unnecessary biopsies.

Screening children and adolescents for cutaneous malignant melanoma: the impossible trade-off between life-years saved and unnecessary biopsies.

The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives.

The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives.

Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions.

Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.